Eli Lilly and Company (NYSE:LLY) today announced positive topline results from its Phase 3b TOGETHER-PsO trial, demonstrating that treating psoriasis and obesity simultaneously yields significantly better outcomes than addressing skin disease alone.
The 36-week trial evaluated the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with moderate-to-severe plaque psoriasis and a mean BMI exceeding 39 kg/m².
The study met its primary endpoint with a striking margin: 27.1% of participants on the combination therapy reached both complete skin clearance (PASI 100) and at least 10% weight loss, compared to just 5.8% of those treated with Taltz alone.
Beyond weight loss, the data suggests that Zepbound may actually enhance Taltz’s efficacy in clearing skin.
In a key secondary endpoint, 40.6% of patients in the combination arm achieved PASI 100, representing a 40% relative increase over the 29.0% success rate seen in the Taltz monotherapy group (p< 0.05).
The safety profile of the dual-treatment approach was consistent with the known effects of each individual drug.